Animalcare Group PLC Daxocox receives positive opinion from CVMP in EU (6321P)

TIDMANCR

RNS Number : 6321P

Animalcare Group PLC

18 February 2021

ANIMALCARE GROUP PLC

(the "Company" or the "Group")

Daxocox receives positive opinion from CVMP in Europe

18 February 2021. Animalcare Group plc (AIM: ANCR), the international animal health business, has received a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) recommending a marketing authorisation for Daxocox (enflicoxib) in Europe.

Daxocox is a novel COX 2 inhibitor and was filed for approval in January 2020 for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs. Following the CVMP's positive opinion, a marketing authorisation decision from the European Commission is anticipated early in the second quarter of 2021. If approved, the authorisation will be valid in all member states of the European Union as well as Norway, Liechtenstein and Iceland.

The equivalent regulatory review of Daxocox for the UK is running largely in parallel with the European Union's schedule and the Group expects a decision on UK marketing authorisation within the same timeframe.

Jenny Winter, Chief Executive Officer said: "This is a hugely important step in the journey to market for Daxocox, a product that has the potential to play a leading role in the Animalcare growth story. Subject to final approval, we plan to launch Daxocox across European markets in the second half of 2021 and expect the product to contribute to revenues before the end of the year."

The development programme for Daxocox is led and managed by the Animalcare team under the pipeline project name, E-6087. Daxocox is the sole property of Animalcare Group plc.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

About Animalcare

Animalcare Group plc is a UK AIM-listed international veterinary sales and marketing organisation. Animalcare operates in seven countries and exports to approximately 32 countries in Europe and a further 16 worldwide. The Group is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.

For more information about Animalcare, please visit www.animalcaregroup.com or contact:

 
 Animalcare Group plc                      +44 (0)1904 487 687 
  Jenny Winter, Chief Executive Officer 
  Chris Brewster, Chief Financial 
  Officer                                   communications@animalcaregroup.com 
  Media relations 
 Stifel Nicolaus Europe Limited 
  (Nominated Adviser & Joint Broker) 
  Ben Maddison 
  Fred Walsh 
  Nick Adams                               +44 (0)20 7710 7600 
 Panmure Gordon 
  (Joint Broker) 
  Corporate Finance 
  Freddy Crossley/Emma Earl 
  Corporate Broking 
  Rupert Dearden                           +44 (0)20 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

REAEASAPFDNFEFA

(END) Dow Jones Newswires

February 18, 2021 10:43 ET (15:43 GMT)

Animalcare (LSE:ANCR)
Historical Stock Chart
From Oct 2024 to Nov 2024